{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:53:54Z","timestamp":1790916834627,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"vor","delay-in-days":163,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014479","name":"Georgia Department of Public Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["5NU58DP006344"],"award-info":[{"award-number":["5NU58DP006344"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101291","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T02:34:55Z","timestamp":1781577295000},"page":"101291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Projected disease burden and treatment eligibility of patients with diffuse large B-cell and mantle cell lymphoma in the United States over the next decade"],"prefix":"10.1016","volume":"48","author":[{"given":"Dan","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changxia","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiemin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Burcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmneh M.","family":"Sineshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101291_bib0002","series-title":"Cancer Stat Facts: Non-Hosgkin Lymohoma","article-title":"Surveillance epidemiology and end results Program","year":"2025"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101291_bib0003","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101291_bib0004","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/ajh.26523","article-title":"Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments","volume":"97","author":"Jain","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101291_bib0005","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101291_bib0006","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12963-025-00415-8","article-title":"Evaluation and forecasting methods to estimate number of patients with non-Hodgkin lymphoma: a systematic literature review","volume":"23","author":"Lin","year":"2025","journal-title":"Popul. Health Metr."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101291_bib0007","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/cncr.27405","article-title":"Predicting US- and state-level cancer counts for the current calendar year: part II: evaluation of spatiotemporal projection methods for incidence","volume":"118","author":"Zhu","year":"2012","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101291_bib0009","doi-asserted-by":"crossref","first-page":"e1092","DOI":"10.1016\/j.clml.2022.08.008","article-title":"An epidemiological model to estimate the prevalence of diffuse large B-cell lymphoma in the United States","volume":"22","author":"Chihara","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101291_bib0010","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1093\/annonc\/mdx333","article-title":"Observation as the initial management strategy in patients with mantle cell lymphoma","volume":"28","author":"Abrisqueta","year":"2017","journal-title":"Ann. Oncol."},{"issue":"Supplement 1","key":"10.1016\/j.ctarc.2026.101291_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-143206","article-title":"Impact of age on treatment and outcome in newly diagnosed DLBCL (Diffuse Large B-cell Lymphoma) patients in the United States veteran population (2011-2017)","volume":"136","author":"Ananth","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.ctarc.2026.101291_bib0012","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1182\/blood-2022-168164","article-title":"Disparities in outcomes of diffuse large B cell lymphoma in adolescent and young adults: a SEER database analysis","volume":"140","author":"Ba Aqeel","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2026.101291_bib0013","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood-2023-187113","article-title":"Treatment intensity and outcomes in elderly patients with DLBCL receiving first line therapy","volume":"142","author":"Bair","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101291_bib0014","doi-asserted-by":"crossref","first-page":"7091","DOI":"10.1007\/s00432-023-04660-y","article-title":"Survival outcomes of patients newly diagnosed with diffuse large B-cell lymphoma: real-world evidence from a German claims database","volume":"149","author":"Borchmann","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"S2","key":"10.1016\/j.ctarc.2026.101291_bib0015","doi-asserted-by":"crossref","DOI":"10.1002\/hon.30_2881","article-title":"Real world outcome in mantle cell lymphoma: a French retrospective study in elderly patients between 2005 and 2018","volume":"39","author":"Branco","year":"2021","journal-title":"Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101291_bib0016","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1080\/10428194.2018.1455973","article-title":"Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma","volume":"59","author":"Calzada","year":"2018","journal-title":"Leukemi.Lymphom."},{"issue":"15","key":"10.1016\/j.ctarc.2026.101291_bib0017","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1002\/cncr.30068","article-title":"Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma","volume":"122","author":"Cohen","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2026.101291_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.824704","article-title":"Real-world estimation of first- and second-line treatments for diffuse large B-cell lymphoma using health insurance data: a Belgian population-based study","volume":"12","author":"Daneels","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2026.101291_bib0019","doi-asserted-by":"crossref","first-page":"8061","DOI":"10.1182\/blood-2022-170521","article-title":"Diffuse large B-cell lymphoma (DLBCL) treatment patterns and outcomes in the oldest-old (\u226585 years): a SEER-Medicare database analysis","volume":"140","author":"Diamond","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2026.101291_bib0020","doi-asserted-by":"crossref","first-page":"10979","DOI":"10.1182\/blood-2022-170446","article-title":"Outcomes and characteristics of untreated diffuse large B-cell lymphoma (DLBCL) patients: a SEER-Medicare database analysis","volume":"140","author":"Diamond","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101291_bib0021","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3109\/10428194.2014.940584","article-title":"Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network","volume":"56","author":"Dreyling","year":"2015","journal-title":"Leuk. Lymphoma"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101291_bib0022","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1634\/theoncologist.2014-0113","article-title":"Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis","volume":"19","author":"Hamlin","year":"2014","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101291_bib0023","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/bjh.18197","article-title":"Outcomes of relapsed\/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-A population-based study of 736 patients","volume":"198","author":"Harrysson","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"Supplement 1","key":"10.1016\/j.ctarc.2026.101291_bib0024","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.1182\/blood-2023-173927","article-title":"Clinical outcomes of patients with newly diagnosed diffuse large B-cell lymphoma in a county hospital system","volume":"142","author":"Jiang","year":"2023","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.ctarc.2026.101291_bib0025","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1803.1803","article-title":"Outcome of initial observation in mantle cell lymphoma","volume":"128","author":"Kumar","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2026.101291_bib0026","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2020-139654","article-title":"Retrospective review of treatment patterns and outcomes of DLBCL in the very elderly: a single centre experience","volume":"136","author":"Manji","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2026.101291_bib0027","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood-2018-99-118411","volume":"132","author":"Martinez","year":"2018","journal-title":"Blood"},{"issue":"SUPPL 2","key":"10.1016\/j.ctarc.2026.101291_bib0028","first-page":"237","article-title":"Rationale for treatment selection, and comorbidities in older patients (PTS) with previously untreated diffuse large B-cell lymphoma (DLBCL): insights from real world data (RWD)","volume":"5","author":"Pace","year":"2021","journal-title":"Hemasphere"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101291_bib0029","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40487-024-00265-8","article-title":"Epidemiology and real-world treatment of incident diffuse large B-cell lymphoma (DLBCL): a German claims data analysis","volume":"12","author":"Pacis","year":"2024","journal-title":"Oncol. Ther."},{"key":"10.1016\/j.ctarc.2026.101291_bib0030","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1182\/blood-2021-151085","article-title":"A comprehensive toxicity and efficacy analysis of different bridging therapies prior to Anti CD19-CAR-T cell therapy in patients with DLBCL- a National Multi-center cohort study","volume":"138","author":"Ram","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101291_bib0031","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/ejh.13649","article-title":"Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival","volume":"107","author":"Shanmugasundaram","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.ctarc.2026.101291_bib0032","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2020-136271","article-title":"Unmet medical need among elderly patients with previously untreated DLBCL characterized using real-world data in the United States","volume":"136","author":"Shewade","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101291_bib0033","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/ejh.14390","article-title":"Factors and considerations in No-treatment decisions in patients with key hematological malignancies: a nationwide, population-based study in the Netherlands","volume":"114","author":"Zijlstra","year":"2025","journal-title":"Eur. J. Haematol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101291_bib0034","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2217\/fon-2023-0191","article-title":"Real-world treatment patterns, survival, health resource use and costs among medicare beneficiaries with diffuse large B-cell lymphoma","volume":"20","author":"Garg","year":"2024","journal-title":"Future Oncol."},{"issue":"13","key":"10.1016\/j.ctarc.2026.101291_bib0035","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1080\/10428194.2019.1623886","article-title":"Temporal trends in treatment and survival of older adult diffuse large B-cell lymphoma patients in the SEER-Medicare linked database","volume":"60","author":"Shaw","year":"2019","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101291_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2025.01.008","article-title":"Improvements in outcomes in older patients with mantle cell lymphoma are associated with Improvements across multiple lines of therapy","volume":"25","author":"Luan","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.ctarc.2026.101291_bib0037","series-title":"Cancer Stat Facts: NHL \u2014 Diffuse Large B-Cell Lymphoma (DLBCL)","article-title":"Surveillance epidemiology and end results Program","year":"2025"},{"key":"10.1016\/j.ctarc.2026.101291_bib0038","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1471-2458-14-102","article-title":"Planning for the future: cancer incidence projections in Switzerland up to 2019","volume":"14","author":"Rapiti","year":"2014","journal-title":"BMC. Public Health"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101291_bib0039","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.4708","article-title":"Estimated projection of US cancer incidence and death to 2040","volume":"4","author":"Rahib","year":"2021","journal-title":"JAMa Netw. Open."},{"key":"10.1016\/j.ctarc.2026.101291_bib0040","doi-asserted-by":"crossref","DOI":"10.5888\/pcd18.210006","article-title":"Cancer incidence projections in the United States between 2015 and 2050","volume":"18","author":"Weir","year":"2021","journal-title":"Prev. Chronic. Dis."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101291_bib0041","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/10428194.2021.1975188","article-title":"Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020\u20132025","volume":"63","author":"Kanas","year":"2022","journal-title":"Leuk. Lymphoma"},{"issue":"Supplement 1","key":"10.1016\/j.ctarc.2026.101291_bib0042","doi-asserted-by":"crossref","first-page":"7618","DOI":"10.1182\/blood-2024-198069","article-title":"Estimating and projecting the number of patients with diffuse large B-cell lymphoma (DLBCL) by treatment lines in the United States","volume":"144","author":"Lu","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101291_bib0043","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101291_bib0044","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/ajh.27075","article-title":"2024 Update: advances in the risk stratification and management of large B-cell lymphoma","volume":"98","author":"Tavakkoli","year":"2023","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101291_bib0045","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101291_bib0046","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1200\/JCO.22.01780","article-title":"High-dose cytarabine and autologous stem-cell transplantation in mantle cell lymphoma: long-term follow-up of the randomized mantle cell lymphoma younger trial of the European mantle cell Lymphoma Network","volume":"41","author":"Hermine","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101291_bib0047","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1200\/JCO.19.01294","article-title":"Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized european MCL elderly trial","volume":"38","author":"Kluin-Nelemans","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101291_bib0048","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000712","article-title":"Long-term outcomes with Ibrutinib treatment for patients with relapsed\/refractory mantle cell lymphoma: a pooled analysis of 3 clinical trials with nearly 10 years of follow-up","volume":"6","author":"Dreyling","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.ctarc.2026.101291_bib0049","unstructured":"Lu J., Do B., Primeaux B. Evaluation of second-generation Bruton's tyrosine kinase inhibitors for the treatment of mantle cell lymphoma. J.Oncol. Pharmacy Practic..0(0):10781552241232331."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101291_bib0050","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","article-title":"Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs","volume":"112","author":"Rollison","year":"2008","journal-title":"Blood"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:59:55Z","timestamp":1790913595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226002029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":48,"alternative-id":["S2468294226002029"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101291","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Projected disease burden and treatment eligibility of patients with diffuse large B-cell and mantle cell lymphoma in the United States over the next decade","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101291","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101291"}}